Lotus International
Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $1.6M Total Trade · DGFT Verified
Lotus International is an Indian pharmaceutical exporter with a total trade value of $1.6M across 9 products in 7 therapeutic categories. Based on 175 verified export shipments from Indian Customs (DGFT) records, Lotus International is the #1 Indian exporter in 1 product including Canagliflozin. Top exports include Extract ($368.5K), Semaglutide ($361.5K), Empagliflozin ($227.9K).
Lotus International — Export Portfolio & Destination Treemap
Who is Lotus International? — Company Overview & Market Position
Lotus International, established in 1991, is a Mumbai-based pharmaceutical exporter specializing in both branded and generic medicines. The company is ISO 9001:2015 certified and recognized as a Two Star Export House by the Government of India, reflecting its commitment to quality and international trade standards. Lotus International offers a diverse range of pharmaceutical formulations, including oncology products, vaccines, COVID-19 treatments, specialty drugs, and veterinary medicines. Its export markets encompass regions such as the Commonwealth of Independent States (CIS), Africa, Latin America, Southeast Asia, and the Middle East.
What Does Lotus International Export? — Product Portfolio Analysis
Lotus International Therapeutic Categories — 7 Specializations
Lotus International operates across 7 therapeutic categories, with Advanced Diabetes Medications (35.5%), Ayurvedic & Herbal Products (22.8%), Diabetes & Endocrine (14.1%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 84% of total exports.
Advanced Diabetes Medications
3 products · 35.5% · $572.8K
Ayurvedic & Herbal Products
1 products · 22.8% · $368.5K
Diabetes & Endocrine
1 products · 14.1% · $227.9K
Diuretics
1 products · 12.5% · $202.5K
Advanced Antibiotics
1 products · 9.3% · $150.0K
Antivirals
1 products · 4.2% · $67.8K
Advanced Oncology
1 products · 1.5% · $24.9K
Product Portfolio — Top 9 by Export Value
Lotus International exports 9 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 1 products.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Extract | Ayurvedic & Herbal Products | $368.5K | 33 | 3.0% | 9 |
| 2 | Semaglutide | Advanced Diabetes Medications | $361.5K | 28 | 7.3% | 3 |
| 3 | Empagliflozin | Diabetes & Endocrine | $227.9K | 11 | 3.4% | 8 |
| 4 | Torsemide | Diuretics | $202.5K | 52 | 1.1% | 6 |
| 5 | Canagliflozin | Advanced Diabetes Medications | $192.4K | 16 | 21.8% | 1 |
| 6 | Ertapenem | Advanced Antibiotics | $150.0K | 3 | 0.1% | 11 |
| 7 | Valacyclovir | Antivirals | $67.8K | 13 | 0.1% | 14 |
| 8 | Mercaptopurine | Advanced Oncology | $24.9K | 6 | 4.2% | 4 |
| 9 | Saxagliptin | Advanced Diabetes Medications | $18.9K | 13 | 0.5% | 3 |
Lotus International exports 9 pharmaceutical products across 7 therapeutic categories with a total export value of $1.6M. The company is the #1 Indian exporter in 1 product: Canagliflozin. The top category is Advanced Diabetes Medications (35.5% of portfolio), followed by Ayurvedic & Herbal Products (22.8%), indicating a concentrated portfolio with the top 5 products accounting for 83.8% of total export value.
Key Metrics
Top Categories
Top Export Routes
Related Analysis
Need Detailed Data?
Shipment-level records, pricing & buyer contacts for Lotus International.
Request DemoLotus International — Corporate Profile & Information
Headquarters, ownership, manufacturing facilities, and key leadership
1Corporate Overview
Lotus International, established in 1991, is a Mumbai-based pharmaceutical exporter specializing in both branded and generic medicines. The company is ISO 9001:2015 certified and recognized as a Two Star Export House by the Government of India, reflecting its commitment to quality and international trade standards. Lotus International offers a diverse range of pharmaceutical formulations, including oncology products, vaccines, COVID-19 treatments, specialty drugs, and veterinary medicines. Its export markets encompass regions such as the Commonwealth of Independent States (CIS), Africa, Latin America, Southeast Asia, and the Middle East.
2Manufacturing Facilities
While specific details about Lotus International's manufacturing facilities are not publicly disclosed, the company emphasizes its capability to supply both branded products from major pharmaceutical companies and to manufacture generics tailored to client requirements. This suggests that Lotus International collaborates with various manufacturing partners to ensure a diverse and adaptable product portfolio.
3Key Leadership
The available information does not provide specific names of the CEO, CFO, or other key executives at Lotus International. However, the company's leadership is described as dedicated to fostering a dynamic, change-driven culture committed to meeting the needs of all stakeholders and becoming a leading pharmaceutical company among the top five in Asia.
Where Does Lotus International Export? — Destination Intelligence
Regulated market presence, emerging market penetration, and geographic strategy
1Regulated Markets
Lotus International's export activities are subject to various regulatory approvals in the United States, European Union, United Kingdom, Australia, and Japan. The company is ISO 9001:2015 certified, indicating adherence to international quality management standards. Additionally, Lotus International has established partnerships in nearly every global market, including the U.S., Europe, Japan, China, and Brazil, reflecting its extensive regulatory compliance and market access.
2Emerging Markets
Lotus International has a significant presence in emerging markets, exporting to regions such as Africa, Latin America, Southeast Asia, and the Middle East. The company's ISO 9001:2015 certification and recognition as a Two Star Export House by the Government of India underscore its commitment to quality and regulatory compliance, facilitating access to these markets.
3Geographic Strategy
Lotus International's geographic strategy demonstrates a diversified approach, with exports spanning multiple continents, including Africa, Latin America, Southeast Asia, and the Middle East. This diversification mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The company's ISO 9001:2015 certification and recognition as a Two Star Export House by the Government of India further support its strategic direction.
Lotus International — Manufacturing & Regulatory Profile
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
1FDA Status
Specific details regarding Lotus International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's ISO 9001:2015 certification indicates adherence to international quality management standards, which is a positive indicator of its commitment to quality.
2WHO & EU GMP
Lotus International's ISO 9001:2015 certification reflects its commitment to quality management systems. However, specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's recognition as a Two Star Export House by the Government of India underscores its compliance with national export standards.
3CDSCO & Indian Regulatory
Lotus International's recognition as a Two Star Export House by the Government of India indicates compliance with national export standards. However, specific details regarding Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available.
4Recent Regulatory Actions
There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with Lotus International. The company's ISO 9001:2015 certification and recognition as a Two Star Export House by the Government of India suggest a commitment to quality and regulatory compliance.
Lotus International — Competitive Positioning Among Indian Pharma Exporters
Market share comparison, key differentiators, and strategic analysis
1Competitive Landscape
Lotus International operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's diverse product portfolio, including oncology products, vaccines, COVID-19 treatments, and specialty drugs, positions it to compete effectively in various therapeutic categories.
2Key Differentiators
Lotus International's key differentiators include its ISO 9001:2015 certification, recognition as a Two Star Export House by the Government of India, and a diverse product portfolio encompassing oncology products, vaccines, COVID-19 treatments, and specialty drugs. These factors underscore the company's commitment to quality, regulatory compliance, and meeting a wide range of healthcare needs.
3Strategic Position
Lotus International's strategic direction focuses on exporting a diverse range of pharmaceutical formulations, including oncology products, vaccines, COVID-19 treatments, and specialty drugs. The company's ISO 9001:2015 certification and recognition as a Two Star Export House by the Government of India reflect its commitment to quality and regulatory compliance. While specific details regarding future strategic initiatives are not publicly available, the company's established presence in various international markets suggests a focus on expanding its global footprint.
Buyer Due Diligence Brief — Evaluating Lotus International as a Supplier
Track record assessment, certifications to verify, and pre-order checks
1Supplier Assessment
Lotus International's track record as an exporter of pharmaceutical formulations is supported by its ISO 9001:2015 certification and recognition as a Two Star Export House by the Government of India. The company's diverse product portfolio, including oncology products, vaccines, COVID-19 treatments, and specialty drugs, indicates a consistent export volume and reliability. However, specific data regarding export volume consistency and reliability indicators are not publicly available.
2Certifications to Verify
Importers should verify the following certifications when considering Lotus International as a supplier:
- ISO 9001:2015 Certification: This certification indicates adherence to international quality management standards. Verification can be done by requesting a copy of the certificate directly from the company.
- Two Star Export House Recognition: This recognition by the Government of India signifies compliance with national export standards. Verification can be done by contacting the Directorate General of Foreign Trade (DGFT) or requesting documentation from the company.
3Due Diligence Checklist
When conducting due diligence on Lotus International, consider the following steps:
- Verify Certifications: Request copies of the ISO 9001:2015 certificate and Two Star Export House recognition.
- Assess Product Portfolio: Review the company's product offerings to ensure they meet your specific requirements.
- Evaluate Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies in your region.
- Check References: Seek feedback from other clients or partners who have worked with Lotus International.
- Inspect Documentation: Review all contractual and shipping documents for accuracy and completeness.
Be cautious of any discrepancies in documentation or communication, as these may indicate potential issues.
Frequently Asked Questions — Lotus International
How many pharmaceutical products does Lotus International export from India?
Lotus International exports 9 pharmaceutical products across 7 therapeutic categories. The top exports are Extract ($368.5K), Semaglutide ($361.5K), Empagliflozin ($227.9K), Torsemide ($202.5K), Canagliflozin ($192.4K). Total export value is $1.6M.
What is Lotus International's total pharmaceutical export value?
Lotus International's total pharmaceutical export value is $1.6M, based on 175 verified shipments recorded in Indian Customs (DGFT) data.
In which products is Lotus International the #1 Indian exporter?
Lotus International is the #1 Indian exporter in 1 products: Canagliflozin (21.8% market share).
What therapeutic categories does Lotus International cover?
Lotus International exports across 7 therapeutic categories. The largest are Advanced Diabetes Medications (35.5%, 3 products), Ayurvedic & Herbal Products (22.8%, 1 products), Diabetes & Endocrine (14.1%, 1 products).
Get Full Lotus International Export Intelligence
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Official References & Regulatory Resources
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Matching: Lotus International identified across shipments using name normalization.
- 2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 3.Market Share: Calculated per product as Lotus International's capped value divided by total Indian exports for that product.
- 4.Shipment Count: Based on 175 individual customs records matching Lotus International.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
9 Products Tracked
7 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Data Source & Methodology
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.